Institute for Clinical and Economic Review Presents Alternative Pricing Models for Remdesivir as a Treatment for COVID-19
May 01, 2020
May 01, 2020
BOSTON, Massachusetts, May 1 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) "cost rec . . .
The Institute for Clinical and Economic Review (ICER) released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) "cost rec . . .